Source comparison
BPC-157 Tendon Repair: Research-Grade vs Clinical-Grade Comparison
Purity Standard ≥98% via HPLC, supplied by facilities like Real Peptides No FDA-approved formulation exists; compounded versions vary Research-grade purity is essential for reproducible outcomes in lab settings Dosage Range 10 mcg/kg to 10 mg/kg body weight in
This comparison does not assign a generated winner or score.
- Purity Standard
- ≥98% via HPLC, supplied by facilities like Real Peptides
- No FDA-approved formulation exists; compounded versions vary
- Research-grade purity is essential for reproducible outcomes in lab settings
- Dosage Range
- 10 mcg/kg to 10 mg/kg body weight in preclinical models
- Human protocols remain off-label; typical range 250–500 mcg/day
- Animal dosing does not directly translate to human equivalents without allometric scaling
- Administration Route
- Subcutaneous, intraperitoneal, or intra-articular in animal studies
- Subcutaneous most common in experimental human use
- Local administration may offer higher site-specific concentrations but systemic delivery still effective
- Regulatory Status
- Not approved for human therapeutic use; research purposes only
- Off-label use only; no Phase III human trials completed
- Legal acquisition requires verification of research-only intent in most jurisdictions
- Efficacy Timeline
- Functional recovery 50% faster in rodent tendon injury models
- Human anecdotal reports suggest similar acceleration but lack controlled data
- Preclinical data is robust; human evidence remains observational